TGFB1 and Myocardial fibrosis: Consequently, although no specific anti-fibrotic drugs are routinely used in HFpEF treatment, targeting the TGF-β1/Smads pathway may be a possible therapeutic strategy to alleviate myocardial fibrosis in HFpEF and deserves further investigation.